Healthcare of Ontario Pension Plan Trust Fund Makes New Investment in Cryoport, Inc. (NASDAQ:CYRX)

Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Cryoport, Inc. (NASDAQ:CYRX) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 440,700 shares of the company’s stock, valued at approximately $7,800,000. Healthcare of Ontario Pension Plan Trust Fund owned 0.89% of Cryoport at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in Cryoport by 2.1% during the 3rd quarter. Vanguard Group Inc. now owns 3,559,092 shares of the company’s stock worth $48,795,000 after buying an additional 74,037 shares during the period. Cadian Capital Management LP increased its position in Cryoport by 30.4% during the 4th quarter. Cadian Capital Management LP now owns 3,464,079 shares of the company’s stock worth $53,659,000 after buying an additional 807,340 shares during the period. Massachusetts Financial Services Co. MA increased its position in Cryoport by 46.9% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,992,895 shares of the company’s stock worth $30,870,000 after buying an additional 636,395 shares during the period. New York State Common Retirement Fund grew its holdings in shares of Cryoport by 29.9% during the 4th quarter. New York State Common Retirement Fund now owns 1,642,752 shares of the company’s stock worth $25,446,000 after purchasing an additional 378,340 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in shares of Cryoport by 487.7% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,393,156 shares of the company’s stock worth $21,580,000 after purchasing an additional 1,156,106 shares in the last quarter. Institutional investors own 92.90% of the company’s stock.

Insider Activity

In other news, Director Richard J. Berman sold 8,105 shares of the firm’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $13.41, for a total transaction of $108,688.05. Following the completion of the transaction, the director now owns 100,000 shares of the company’s stock, valued at $1,341,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Richard J. Berman sold 8,105 shares of the stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $13.41, for a total transaction of $108,688.05. Following the completion of the sale, the director now directly owns 100,000 shares in the company, valued at $1,341,000. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Edward J. Zecchini sold 3,443 shares of the stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $13.37, for a total transaction of $46,032.91. Following the sale, the insider now owns 60,051 shares of the company’s stock, valued at $802,881.87. The disclosure for this sale can be found here. Insiders own 10.10% of the company’s stock.

Cryoport Price Performance

NASDAQ:CYRX traded up $0.48 on Thursday, hitting $9.06. The company had a trading volume of 362,820 shares, compared to its average volume of 589,311. The stock has a market capitalization of $446.30 million, a price-to-earnings ratio of -3.73 and a beta of 1.59. The company has a current ratio of 10.73, a quick ratio of 10.22 and a debt-to-equity ratio of 0.86. The firm has a 50 day moving average of $9.18 and a two-hundred day moving average of $13.66. Cryoport, Inc. has a 52 week low of $5.32 and a 52 week high of $20.10.

Cryoport (NASDAQ:CYRX) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.06). The company had revenue of $54.59 million during the quarter, compared to the consensus estimate of $58.78 million. Cryoport had a negative net margin of 50.17% and a negative return on equity of 15.19%. Cryoport’s revenue for the quarter was down 13.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.16) EPS. On average, research analysts anticipate that Cryoport, Inc. will post -1.35 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently issued reports on CYRX shares. Jefferies Financial Group started coverage on Cryoport in a report on Thursday, April 4th. They set a “buy” rating and a $21.00 target price on the stock. B. Riley lowered Cryoport from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $22.00 to $19.00 in a report on Friday, May 3rd. Finally, Needham & Company LLC reissued a “buy” rating and set a $18.00 target price on shares of Cryoport in a report on Wednesday, May 8th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $19.43.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.